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Objective: This study was undertaken to investigate the role of the angiogenic
factors vascular endothelial growth factor and basic fibroblast growth factor in the
development and progression of Barrett esophagus and adenocarcinomas of the
esophagus and gastroesophageal junction.
Methods: Vascular endothelial growth factor and basic fibroblast growth factor
messenger RNA expression levels, relative to the control gene encoding -actin,
were measured by using a quantitative reverse transcription-polymerase chain
reaction method (ABI 7700 Sequence Detector system) in specimens of Barrett
intestinal metaplasia (n  16), dysplasia (n  11), adenocarcinoma (n  l 5), and
matching normal squamous esophageal tissues (n  35). Vascular endothelial
growth factor and basic fibroblast growth factor protein expression and CD31
microvessel density were assessed by means of immunohistochemistry in 25 tissue
sections that included representative areas for each of these Barrett stages.
Results: Expression levels were significantly increased in adenocarcinoma com-
pared with in either normal squamous mucosa (P  .0001 for both genes) or
intestinal metaplasia (vascular endothelial growth factor, P  .002; basic fibroblast
growth factor, P  .0001). Vascular endothelial growth factor levels were also
significantly higher in cancer tissues compared with dysplasia tissues (P  .024,
Mann-Whitney U test). Basic fibroblast growth factor expression was also signifi-
cantly increased in Barrett dysplastic mucosa compared with in intestinal metaplasia
or normal esophageal mucosa. Microvessel density was generally higher in adeno-
carcinoma compared with in preneoplastic Barrett tissues. The pattern of vascular
endothelial growth factor and basic fibroblast growth factor protein expression was
similar to the messenger RNA expression pattern, with the exception that mucin-
containing goblet cells stained intensely for vascular endothelial growth factor and
only weak vascular endothelial growth factor staining was present in some adeno-
carcinomas.
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Conclusions: Vascular endothelial growth factor and basic fibroblast growth factor
messenger RNA expression levels are significantly upregulated in esophageal and
gastroesophageal junction adenocarcinomas, suggesting a role for these angiogenic
factors in the development of these cancers. Vascular endothelial growth factor and
basic fibroblast growth factor messenger RNA expression levels are also increased
in some Barrett esophagus tissues, with this increase occurring at an earlier stage for
basic fibroblast growth factor than for vascular endothelial growth factor. Basic
fibroblast growth factor protein expression pattern is similar to the messenger RNA
expression pattern, but unlike the messenger RNA findings, vascular endothelial
growth factor protein expression is strongest in goblet cells.
The most significant risk factor for esophagealadenocarcinoma is the presence of Barrettesophagus, a disease in which the normalsquamous lining of the distal esophagus isreplaced with intestinalized columnar epi-thelium in response to chronic gastroesoph-
ageal reflux. Barrett esophagus is a multistage disease in
which Barrett intestinal metaplasia (IM) progresses, in some
patients, to low-grade dysplasia (LGD), high-grade dyspla-
sia (HGD), and eventually adenocarcinoma. Regular sur-
veillance endoscopy in patients with Barrett esophagus has
resulted in an increase in the rate of early detection of
cancer, but endoscopic surveillance fails to detect adeno-
carcinoma in many cases,1 and most cases of Barrett esoph-
agus are undiagnosed and thus not included in a surveillance
program. These clinical problems indicate that reliable di-
agnostic or prognostic biomarkers for Barrett esophagus and
esophageal adenocarcinoma would be valuable.
The density of new vessel formation within and around
tumors (tumor angiogenesis) and the expression of proan-
giogenic factors have been shown in many studies to be
clinically significant biomarkers for esophageal squamous
cell carcinoma (SCC),2-10 but few studies11-13 have investi-
gated these factors in esophageal adenocarcinoma or Barrett
esophagus. In this study we assessed the expression of 2
important proangiogenic factors, vascular endothelial
growth factor (VEGF; also known as vascular permeability
factor)14-17 and basic fibroblast growth factor (bFGF),18 in
Barrett IM, dysplasia, and adenocarcinoma tissues to inves-
tigate the potential significance of these factors in the de-
velopment and progression of this disease.
Materials and Methods
Tissue Samples for Reverse Transcription-Polymerase
Chain Reaction
Seventy-seven tissue samples obtained at endoscopy and at the
time of the operation from 38 patients with Barrett esophagus or
adenocarcinoma of the esophagus or gastroesophageal junction
were collected and immediately frozen in liquid nitrogen. Endo-
scopic biopsy specimens were obtained according to a protocol
that required biopsy at 2-cm intervals from each quadrant (anterior,
posterior, and right and left lateral positions) of the visible length
of Barrett mucosa and an additional biopsy specimen from the
normal-appearing squamous mucosa of the esophagus. Normal
esophageal biopsy specimens were taken from the proximal mar-
gin of the operative resection specimens or from an area at least 4
cm proximal to the macroscopically abnormal epithelium on en-
doscopy. Part of the specimen or an adjacent specimen (from
within 5 mm of the study specimen) was fixed in formalin and
paraffin for histopathologic examination by expert Barrett pathol-
ogists. Frozen-section examination of the study tissue was per-
formed if the diagnosis was uncertain. Specimens were classified
as IM if IM but not dysplasia or cancer was present. Specimens
were classified as dysplastic if either LGD or HGD was present.
Dysplastic tissues were not divided into HGD and LGD groups
because areas of LGD and HGD were commonly present in the
same specimen. The fresh tumor specimens were macrodissected
to ensure that the specimen analyzed contained mostly tumor cells.
By using these criteria, samples analyzed for VEGF and bFGF
expression were Barrett IM (n  16), Barrett dysplasia (n  ll),
esophageal or gastroesophageal junction adenocarcinoma tissues
(n  15), and matching normal esophagus tissues from 35 of the
patients (n  35). The IM samples were all from patients who did
not have dysplasia or adenocarcinoma. Four of the 11 dysplasia
samples were from patients with adenocarcinoma. Of the 35 nor-
mal squamous esophageal samples, 22 were obtained from patients
with Barrett metaplasia or dysplasia but no adenocarcinoma, and
13 were from patients with adenocarcinoma.
Approval for this study was obtained from the Institutional
Review Board of the University of Southern California Keck
School of Medicine, and written informed consent was obtained
from participating patients.
RNA Extraction and cDNA Synthesis
Total RNA was isolated by using a single-step guanidinium iso-
thiocyanate method with the QuickPrepmMicro mRNA Purifica-
tion Kit (Amersham Pharmacia Biotech Inc, Piscataway, NJ),
according to the manufacturer’s instructions, and cDNAs were
prepared as previously described.19,20
PCR Quantification of mRNA Expression
Quantitation of VEGF and bFGF cDNA and an internal reference
cDNA (-actin) was done by using a fluorescence detection
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method (ABI PRISM 7700 Sequence Detection System, Taqman;
Perkin Elmer Applied Biosystems, Foster City, Calif), as previ-
ously described.20-22
The PCR reaction mixture consisted of 600 nmol/L of each
primer; 200 nmol/L probe; 5 U of AmpliTaq Gold Polymerase;
200 pmol/L each of deoxyadenosine triphosphate, deoxycytidine
triphosphate, and deoxyguanosine triphosphate; 400 mol/L
dUTP (2-deoxyuridine 5-triphosphate), 5.5 mmol/L MgCl2; 1 U
of AmpErase uracil N-glycosylase; and 1 Taqman Buffer A
containing a reference dye to a final volume of 25 L (all reagents
were obtained from ABI Applied Biosystems, Foster City, Calif).
Cycling conditions were 50°C for 2 minutes and 95°C for 10
minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C
for 1 minutes. Significant contamination with genomic DNA was
excluded by amplifying non-reverse-transcribed RNA. Primer and
probe sequences are available on request.
The reproducibility of the Taqman assay was tested by mea-
suring VEGF mRNA expression in 5 tumor samples and 6 control
RNAs (2 colon RNAs, 2 liver RNAs, and 2 lung RNAs; Strat-
agene, La Jolla, Calif) in triplicate.
Immunohistochemistry
Five representative areas of each histopathologic stage (normal
squamous esophagus, Barrett IM, LGD, HGD, and adenocarci-
noma) were stained by means of immunohistochemistry to show
the patterns of microvessel density, VEGF protein expression, and
bFGF protein expression. Archival formalin-fixed, paraffin-em-
bedded blocks were cut into 5-m sections, mounted onto polyl-
ysine-coated slides, dewaxed in xylene, and rehydrated in alcohol.
Pretreatment by immersion in 10 mmol/L citrate buffer (pH 6.0)
with microwave pressure cooker heating was performed for stain-
ing with the CD31 (platelet-endothelial adhesion molecule, clone
JC/70A, 1:100 dilution; DAKO, Carpinteria, Calif) and bFGF
(Ab-3, Clone 3H3, 1:50 dilution; Oncogene Research, San Diego,
Calif) antibodies. Pretreatment by means of microwave heating in
10 mmol/L ethylenediamine tetraacetic acid (pH 8.0) was per-
formed for staining with the VEGF (Clone JH121, 1:100 dilution,
Ab-3; Neomarkers, Fremont, Calif) antibody. The sections were
peroxidase blocked with 3% hydrogen peroxide in 0.05 mol/L
TRIS-hydrochloric acid buffer, incubated for 15 minutes with
normal horse serum, and incubated with primary antibody (all
overnight at room temperature). Biotinylated horse anti-mouse
secondary antibody (1:200 dilution for 40 minutes; Vector Labs,
Burlingame, Calif), peroxidase-conjugated streptavidin complex
reagent (1:100 dilution, 30 minutes, VectaStain Elite ABC Kit,
Vector Labs), and 3.3-diaminobenzidine (10 mg in 10 mL of
TRIS buffer for 20 minutes) were used to visualize binding of the
first antibody. Positive and negative controls were used for each
antibody.
Areas of highest neovascularization, as assessed by means of
CD31 positivity, were found by scanning each section at 100
magnification. Microvessel density was then quantified in these
neovascular hot spots at 400 magnification. At least 2 different
fields of hot spots were evaluated for each case to obtain the mean
number of CD31 microvessels per section. For counting positive-
staining vessels, only those with at least one visible endothelial cell
were considered.
The intensity of VEGF and bFGF cytoplasmic protein expres-
sion was graded as 0 (staining intensity not above background
level), 1 (weak uniform staining, slightly above background
staining), 2 (moderate uniform staining), or 3 (strong uniform
staining). The intensity classification for each section was based on
the highest intensity staining area for the section. The staining
patterns in both epithelial and endothelial cells were assessed.
Statistical Analysis
VEGF and bFGF mRNA expression levels in adenocarcinoma,
Barrett dysplasia, IM, and normal squamous esophageal tissues
were compared by using the Kruskal-Wallis test to identify sig-
nificant differences in expressions among all histopathologic
groups. The Mann-Whitney U test was then used to compare the
expression levels between 2 different groups. VEGF and bFGF
expressions in premalignant Barrett and histologically normal
squamous esophageal tissues from patients with Barrett esophagus
but no cancer were compared with the expressions in these tissues
from patients with cancer in a second analysis that used the same
statistical methods. Reproducibility of the assay, as tested with
triplicate VEGF assays in clinical specimens and control RNAs,
TABLE 1. Comparison of VEGF and bFGF mRNA expression levels in different tissues
Pathology
No. of
tissues
VEGF,
median
(range)
bFGF,
median
(range) Tissues compared
VEGF
P value
bFGF
P value
Adenocarcinoma 15 57.6 7.13 Adenocarcinoma vs normal esophagus;
adenocarcinoma vs dysplasia;
adenocarcinoma vs IM
.0001 .0001
(14-287) (0.51-54.44) .024 .28
.002 .0001
Barrett esophagus
with dysplasia
11 16.4 4.0 Dysplasia vs normal esophagus;
dysplasia vs IM
.76 .007
(2-616) (0.18-18.54) .75 .009
Intestinal metaplasia 16 28.3 0.85 IM vs normal esophagus .32 .73
(8-140) (0.15-6.59)
Normal esophagus 35 17.8 1.0 — —
(2-103) (0.01-24)
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was assessed by calculating the coefficient of variance of the
threshold cycle for each reverse transcription-polymerase chain
reaction (RT-PCR) analysis.
Results
RT-PCR Results
The median values and ranges of VEGF and bFGF
mRNA expressions in adenocarcinoma (n  15), Barrett
dysplasia (n  11), Barrett IM (n  16), and normal
squamous esophagus epithelial (n  35) tissues are shown
in Table 1. As shown, the RNA expression levels of both
VEGF and bFGF were significantly upregulated in the
group of adenocarcinoma tissues compared with in the
group of normal squamous esophageal (P  .0001 for both
genes) or Barrett IM tissues (P  .0001 for bFGF and P 
.002 for VEGF). VEGF expression, but not bFGF expres-
sion, was also significantly higher in adenocarcinoma com-
pared with that in dysplastic Barrett esophagus mucosa
(P  .009 for VEGF).
bFGF mRNA expression levels were significantly higher
in dysplasia tissues than in normal esophageal or IM tissues
(Table 1). There was considerable variability in mRNA
expression levels for both genes within each histopathologic
stage, and very high measurements were recorded in some
specimens from all tissue types.
The bFGF mRNA expression levels in the group of
histologically normal squamous esophageal tissues from
patients with adenocarcinoma (n  13; median expression,
3.3) was significantly higher than the levels found in normal
esophageal tissues from patients with Barrett IM or dyspla-
sia but no cancer (n  22; median expression, 0.21; P 
.0001). There was no significant difference in VEGF RNA
expression found between these 2 normal esophageal epi-
thelium groups (P  .58), and there was no significant
expression level difference found between dysplasia tissues
from patients with cancer and dysplasia tissues from pa-
tients without cancer (P  .23 for both VEGF and bFGF).
No IM specimens from patients with adenocarcinoma or
dysplasia were studied.
Reproducibility of the Taqman Assay
The mean coefficient of variance of the PCR Taqman
threshold cycles for RNAs run in triplicate for VEGF RNA
expression was 0.39% (median, 0.30%) for the control
specimens and 0.41% (median 0.26%) for the esophageal
adenocarcinoma specimens (data available on request).
Immunohistochemistry Results
Representative immunohistochemistry sections are shown
in Figure 1.
As expected, intense CD31 positivity was restricted to
endothelial cells. Moderate or strong (2 or 3 intensity)
microvessel CD31 immunoperoxidase staining with low
background staining was present in all the sections. Table 2
shows the average numbers of CD31 vessels found within
each histopathologic tissue type. The microvessel density
was generally higher in adenocarcinoma than in preneoplas-
tic Barrett epithelium, with 4 of 5 tissues having microves-
sel counts higher than the median microvessel count for all
25 tissues studied (median, 10 vessels per high-power field),
but 2 of 5 LGD and 1 of 5 HGD tissues also had microvessel
counts of greater than the median value (Table 2). There
was a high concentration of CD31 vessels within the
TABLE 2. Immunohistochemistry results in 25 esophageal tissues
Antibody
Histopathology
Normal
esophagus IM* LGD* HGD* Adenocarcinoma
CD31 (average number of vessels/high power field)†
Case 1 9 6 2 8 9
Case 2 12 7 6 8 13
Case 3 13 7 10 8 14
Case 4 14 8 14 9 16
Case 5 15 10 19 12 16
VEGF intensity of epithelial cell staining (no. of cases/total 5 cases for each histopathology)
0 4 cases 3 cases 3 cases 4 cases —
1 1 case 1 case 2 cases 1 case 3 cases
2 — 1 case — — 1 case
3 — — — — 1 case
bFGF intensity of epithelial cell staining (no. of cases/total 5 cases for each histopathology)
0 4 cases 2 cases 2 cases 1 case —
1 1 case 3 cases — 1 case —
2 — — 2 cases 1 case 2 cases
3 — — 1 case 2 cases 3 cases
*Not including goblet cells in Barrett epithelium. Goblet cells generally stained intensely for VEGF and moderately for bFGF (see text).
†High-power field  400  magnification. Averages rounded to whole numbers.
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subepithelium of the normal squamous mucosa (Table 2 and
Figure 1) because the surface area of lamina propria, where
the vessels are located, was much higher in squamous
mucosa than in Barrett mucosa or adenocarcinoma. Tumor
angiogenesis was heterogeneous, but areas of highest neo-
vascularization (neovascular hot spots) were most fre-
quently found at the margins of the adenocarcinomas.
VEGF staining was only weakly positive in 3 of 5
adenocarcinoma cases, but the intensity of staining in ade-
nocarcinoma was nevertheless generally stronger than
found in nongoblet columnar cells in Barrett esophagus or
normal squamous mucosa (Table 2 and Figure 1). Mucin-
containing goblet cells stained very intensely for VEGF.
VEGF stained microvessel endothelial cells faintly. The
concentration of VEGF-positive microvessels was highest
in Barrett IM, followed by dysplastic Barrett, and lowest in
adenocarcinoma.
bFGF showed intense staining in the malignant cells of
adenocarcinoma, less intense but definite staining in LGD
and HGD columnar cells, and faint staining in goblet cells
(Table 2 and Figure 1). bFGF staining was present in the
basal squamous layer in one normal esophagus case. bFGF
positivity, including some moderately intense positivity,
was found in endothelial cells in each histopathologic tissue
type.
Discussion
This study demonstrates that mRNA expression levels of
VEGF and bFGF are significantly upregulated in most ad-
enocarcinomas of the esophagus or gastroesophageal junc-
Figure 1. Representative immunohistochemistry sections: A, normal squamous esophagus; B, Barrett IM with goblet
cells; C, esophageal adenocarcinoma; i, CD31 microvessel density, showing specific endothelial cell staining; ii,
VEGF protein expression; iii, bFGF protein expression.
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tion. There was considerable variation in expression levels
for both genes at all histopathologic stages, but analysis of
the grouped results for each stage showed that there was a
highly significant increase in both VEGF and bFGF expres-
sion in adenocarcinoma tissues compared with normal
esophageal or Barrett IM tissues. A study by Torres and
colleagues11 found high new vessel densities in esophageal
adenocarcinomas. Because VEGF and bFGF have critically
important roles in inducing and maintaining angiogenesis, it
is likely that the increased expression of these genes found
in our study is causally associated with the tumor angiogen-
esis reported by Torres and colleagues.
As might be expected for a complex biologic process,
there was no close correlation between the levels of VEGF
and bFGF expression in individual patients in this study,
indicating that there is little diagnostic value in measuring
the expression of these genes for an individual patient.
Assessment of a panel of informative genes should theoret-
ically be more useful for individual patients.
Most of the patients with cancer had markedly increased
levels of both VEGF and bFGF. Upregulation of both genes
together suggests that their regulation might not be inde-
pendent, a theory that is supported by the finding that bFGF
can induce the expression of VEGF.23 In vitro angiogenesis
assay studies have also demonstrated synergism between
VEGF and bFGF.24,25
In contrast to the similar marked upregulation in the
expression of both genes in cancer tissues, there were some
differences between the expression patterns of each gene in
premalignant Barrett tissues. A significantly increased
bFGF expression was found in the group of dysplastic
Barrett tissues compared with either IM or normal esopha-
gus groups, whereas for VEGF, there was no significant
increase in expression in dysplastic tissues. Some individual
patients had very high expression levels of either or both
genes in IM or dysplastic epithelia. Because of the wide
variability in gene expression between individual patients
with the same histopathologic Barrett stage, it is acknowl-
edged that analysis of tissues from a much larger number of
patients could produce a different pattern of expression for
the premalignant stages. Nevertheless, our results suggest
that VEGF expression, although high in some Barrett
esophagus specimens, is not consistently overexpressed un-
til the Barrett epithelium acquires an invasive phenotype.
This might occur at the time of the angiogenic switch, when
the tumor recruits new capillaries and is thus able to ex-
pand.26 bFGF expression, in contrast, is upregulated more
frequently at the dysplasia stage, before the development of
invasive cancer and perhaps before the onset of the switch
to an angiogenic phenotype. Interestingly, other studies
report that tumor angiogenesis can be detected in hyperpro-
liferative and morphologically transformed but noninvasive
cells.26,27
bFGF expression levels were significantly higher in this
study in the group of histologically normal squamous
esophageal tissues from patients with cancer compared with
in the group of histologically normal squamous esophageal
tissues from patients without cancer. These results indicate
that some genetic changes precede the appearance of even
the earliest morphologic changes in this disease. The normal
esophageal biopsy specimens were from areas that were
well separated from macroscopic disease, indicating that
there is probably a very widespread oncogenic field effect in
the esophagus in patients with cancer. Other studies have
found similar evidence for the presence of a cancer field in
esophageal adenocarcinoma.20,28-31
A relatively small number of sections were stained for
immunohistochemistry, and the protein expression findings
are therefore not conclusive. Nevertheless, it is evident that
bFGF mRNA and protein expression patterns are similar,
with maximal expression in adenocarcinoma and dysplastic
Barrett cells. In contrast to the mRNA findings and for
unknown reasons, VEGF expression was maximal in the
mucin in goblet cells. As expected, CD31 microvessel
density, a measure of tumor angiogenesis, was generally
higher in adenocarcinoma than in Barrett esophagus.
This study was not designed to investigate mechanisms
regulating VEGF or bFGF. It can be noted, however, that
some genetic alterations known to induce VEGF expres-
sion, including p53 mutations and erbB2/Her2/neu overex-
pression,32 are frequently present in adenocarcinomas of the
esophagus and gastroesophageal junction; ras mutation sta-
tus can influence VEGF expression,32,33 but the frequency
of ras mutation in this disease is uncertain.34,35 There is also
evidence that angiogenesis can be regulated by cyclooxy-
genase 2 (COX-2) expression,36,37 which is upregulated in
both esophageal adenocarcinoma and Barrett esopha-
gus.38,39 These observations suggest future areas for inves-
tigation in this disease, and they also suggest that combina-
tion therapies targeting both angiogenesis and angiogenic
regulators, such as COX-2, ras, or erbB2/HER-2/neu, might
be more effective than single-agent therapies alone. Ziche
and associates40 noted that because the agents that can
modulate angiogenesis are heterogeneous with respect to
their chemical characteristics and biologic properties, quan-
titative measurement of angiogenesis factors would be help-
ful for selecting specific angiogenesis therapies and as an
end point for antiangiogenic therapy. Our data indicate that
the quantitative RT-PCR system used in this study would be
suitable for this purpose.
The development of esophageal and gastroesophageal
junction adenocarcinomas is associated with the expression
of the angiogenic factors VEGF and bFGF. Some prema-
lignant Barrett esophagus tissues also express high levels of
these genes, with increased bFGF expression associated
with the dysplastic Barrett phenotype. Further studies on
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this important multistage carcinogenesis model are required
to confirm the effect of VEGF and bFGF expression on
angiogenesis itself, to determine the mechanisms regulating
the expression of these genes, and to identify associations
between angiogenesis and clinical outcomes.
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Discussion
Dr Robert J. Keenan (Pittsburgh, Pa). Because your endo-
thelial or vascular markers are really not specific from the stand-
point of trying to determine the dysplastic changes from the
adenocarcinoma-type changes, can you tell us how you might use
this information if you have patients under surveillance who have
Barrett esophagus without dysplastic changes to try to determine
when you should intervene? The big controversy, of course, is that
at some point we believe that if you get to the point of HGD, that
in many cases this means that you already have adenocarcinoma
somewhere in there, and people are talking about esophagectomy.
Can you use this information in a way to try to help you determine
who it is that is likely to go on to that kind of a course?
Dr Lord. Thank you. As you suggest is needed, many groups
are looking for a biomarker that is specific for cancer, one that is
present in malignant tissues but not in patients with high-grade
dysplasia or other Barrett epithelia. Unfortunately, because there
were some very high levels in dysplasia patients, we do not think
that VEGF and basic FGF are going to be able to fulfill this role.
We have found other genes, for example telomerase, the gamma
retinoic acid receptor, and also to some extent COX-2, for which
very abnormal levels are only found in patients with cancer, and at
this stage those markers offer more promise. We have also con-
ducted a multicenter serum study that looked at the methylated
APC gene. So far, methylated APC has only been present in the
serum in patients with cancer. It was not present in patients with
premalignant Barrett esophagus or benign gastric diseases. So at
the moment, we concede that the factors presented today by
themselves do not offer enormous clinical utility, but there are
other more promising factors. We think that ultimately there will
be a panel of informative expression factors and with a large
enough data set it will be possible to set limits above and below
which we can reasonably accurately predict which patients have
cancer and which patients are at higher risk for developing cancer.
Dr Nasser K. Altorki (New York, NY). I have noticed that your
confidence intervals are quite large. Therefore although it is an
interesting work, I think it needs to be validated by larger numbers.
A few years back, we published an article on the expression of
acidic and bFGF by means of immunohistochemistry and also by
looking at the mRNA. We found that bFGF has a lot of mRNA
expression, but we were not able to find it by means of immuno-
histochemistry. I wonder what happens to the mRNA. Is it stable,
or is it just not transcribed? Did you have a chance to look at
whether the mRNA is actually present and whether the protein is
actually present?
Dr Lord. We are in the process of doing that, and I do not think
we have sufficient information at the moment to answer your
question adequately. Certainly there does seem to be a correlation
between angiogenesis factor expression and microvessel density
measured with CD31. In addition to your study, a paper by Torres
and associates looked specifically at adenocarcinoma and squa-
mous cell carcinoma of the esophagus. Torres and colleagues also
found that microvessel density was significantly increased in ad-
enocarcinoma tissues.
Dr David S. Schrump (Bethesda, Md). I have 2 related ques-
tions that are very brief.
I saw that you had acknowledged that p53, as well as HER-2/
neu, mutations correlate with induction of VEGF and bFGF ex-
pression. Have you performed or do you plan to perform an
analysis for p53, as well as your her-2/neu expression, in your
mRNA samples to try to correlate the levels of VEGF and bFGF
expression to these mutational events?
Dr Lord. Yes, we are interested in doing that. We do not intend
to sequence these recently collected tissues themselves, but we do
have now a group of approximately 50 adenocarcinomas that have
been sequenced for at least exons 5 to 8 that were collected several
years ago. The Danenberg laboratory where this work was done
has recently developed a methodology to isolate RNA from par-
affin sections, so we think that it will be possible to correlate the
expression of these factors with the presence of a p53 mutation in
the patients for whom we already have the p53 information. We
also have information on COX-2 expression in a large number of
tissues. So we do intend to pursue those interesting questions.
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